BridgeBio Pharma Inc

Latest Results (15.05.2026):

BridgeBio Pharma Inc — Q4 2025: BridgeBio reported strong commercial revenue growth in the fourth quarter of 2025 with total Q4 revenues of $154.2 million and full-year 2025 revenues of $502.1 million, driven primarily by Attruby net product sales ($146.0M Q4; $362.4M FY). The company remains unprofitable: net loss attributable to common stockholders was $192.9 million in Q4 2025 and $724.9 million for the full year (EPS of $(1.00) and $(3.78), respectively). BridgeBio ended 2025 with $587.5 million in cash, cash equivalents and marketable securities and subsequently completed the issuance of convertible notes in January 2026 to bolster liquidity for commercial and pipeline activities.

Total revenues (Q4 & FY 2025)

Q4 2025 total revenues, net: $154.2 million (up from $5.9M in Q4 2024). FY 2025 total revenues, net: $502.1 million (up from $221.9M in 2024). The increase was driven mainly by Attruby net product revenue ($146.0M Q4; $362.4M FY), plus modest royalty and license/service contributions.

Profitability and EPS

Net loss attributable to common stockholders: $192.9M in Q4 2025 and $724.9M for FY 2025 (basic and diluted net loss per share: $(1.00) Q4; $(3.78) FY). Losses reflect heavy investment in commercialization and ongoing R&D/program reprioritization adjustments.

Operating costs and expense drivers

Total operating costs and expenses: $293.7M in Q4 2025 and $1.025B for FY 2025. SG&A rose sharply (Q4 SG&A $158.1M; FY $531.2M) driven by Attruby commercial launch and related investments. R&D declined (Q4 R&D $116.4M; FY $452.0M) due mainly to reduced Attruby/BEYONTTRA program spend and program reprioritization. Restructuring/impairment charges increased modestly.

Other income/(expense) and notable balance-sheet items

Total other expense, net: $(55.2)M in Q4 2025 and $(209.1)M for FY 2025, driven by noncash interest on deferred royalty obligations and equity-method losses. Deferred royalty obligations stood at $855.0M (as of 12/31/2025). The Company reported a stockholders' deficit of approximately $2.09 billion as of December 31, 2025.

Cash, liquidity and financing

Cash, cash equivalents and marketable securities: $587.5M as of December 31, 2025 (down from $681.1M at 12/31/2024). Net cash used in operating activities for 2025: $445.9M. In January 2026 the company completed issuance of $632.5M aggregate principal amount of 2033 convertible notes (announced in the report) to extend maturities and support planned commercial/pipeline activities.

Commercial traction — Attruby

Attruby continues to be the revenue engine: Q4 net product revenue $146.0M (35% quarter-over-quarter growth reported), and as of Feb 20, 2026 there were 7,804 unique patient prescriptions written by 1,856 unique prescribers since FDA approval. Management cites rapid prescribing growth, repeat use and patient persistence as drivers of momentum.

Near-term milestones that could affect finances

BridgeBio plans multiple near-term regulatory filings and potential launches: intended NDA submissions for BBP‑418 and encaleret in 1H 2026, infigratinib in 2H 2026, with anticipated U.S. launches for several programs in late 2026/early 2027 if approved—each outcome could materially affect future revenue and cash burn trajectory.